112 related articles for article (PubMed ID: 29101238)
1. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
[TBL] [Abstract][Full Text] [Related]
2. Glutathione S-transferase M1 inhibits dexamethasone-induced apoptosis in association with the suppression of Bim through dual mechanisms in a lymphoblastic leukemia cell line.
Hosono N; Kishi S; Iho S; Urasaki Y; Yoshida A; Kurooka H; Yokota Y; Ueda T
Cancer Sci; 2010 Mar; 101(3):767-73. PubMed ID: 20067466
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling.
Abdoul-Azize S; Hami R; Riou G; Derambure C; Charbonnier C; Vannier JP; Guzman ML; Schneider P; Boyer O
Nat Commun; 2024 May; 15(1):4557. PubMed ID: 38811530
[TBL] [Abstract][Full Text] [Related]
4. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
Gocho Y; Liu J; Hu J; Yang W; Dharia NV; Zhang J; Shi H; Du G; John A; Lin TN; Hunt J; Huang X; Ju B; Rowland L; Shi L; Maxwell D; Smart B; Crews KR; Yang W; Hagiwara K; Zhang Y; Roberts K; Wang H; Jabbour E; Stock W; Eisfelder B; Paietta E; Newman S; Roti G; Litzow M; Easton J; Zhang J; Peng J; Chi H; Pounds S; Relling MV; Inaba H; Zhu X; Kornblau S; Pui CH; Konopleva M; Teachey D; Mullighan CG; Stegmaier K; Evans WE; Yu J; Yang JJ
Nat Cancer; 2021 Mar; 2(3):284-299. PubMed ID: 34151288
[TBL] [Abstract][Full Text] [Related]
5. Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression.
Toscan CE; Jing D; Mayoh C; Lock RB
Br J Cancer; 2020 Jun; 122(12):1769-1781. PubMed ID: 32242100
[TBL] [Abstract][Full Text] [Related]
6. A New Indole Derivative, LWX-473, Overcomes Glucocorticoid Resistance in Jurkat Cells by Activating Mediators of Apoptosis.
Song J; Yang K; Gajendran B; Varier KM; Li W; Liu Q; Rao Q; Hang Y; Shen X; Liu S; Huang L; Xu M; Li Y
Front Biosci (Landmark Ed); 2024 Apr; 29(4):163. PubMed ID: 38682179
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.
Meyer LK; Huang BJ; Delgado-Martin C; Roy RP; Hechmer A; Wandler AM; Vincent TL; Fortina P; Olshen AB; Wood BL; Horton TM; Shannon KM; Teachey DT; Hermiston ML
J Clin Invest; 2020 Feb; 130(2):863-876. PubMed ID: 31687977
[TBL] [Abstract][Full Text] [Related]
8. Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL.
Accordi B; Espina V; Giordan M; VanMeter A; Milani G; Galla L; Ruzzene M; Sciro M; Trentin L; De Maria R; te Kronnie G; Petricoin E; Liotta L; Basso G
PLoS One; 2010 Oct; 5(10):e13552. PubMed ID: 21042412
[TBL] [Abstract][Full Text] [Related]
9. CD9 shapes glucocorticoid sensitivity in pediatric B-cell precursor acute lymphoblastic leukemia.
Zhang C; Chan KYY; Ng WH; Cheung JTK; Sun Q; Wang H; Chung PY; Cheng FWT; Leung AWK; Zhang XB; Lee PY; Fok SP; Lin G; Poon ENY; Feng JH; Tang YL; Luo XQ; Huang LB; Kang W; Tang PMK; Huang J; Chen C; Dong J; Mejstrikova E; Cai J; Liu Y; Shen S; Yang JJ; Yuen PMP; Li CK; Leung KT
Haematologica; 2024 Apr; ():. PubMed ID: 38572553
[TBL] [Abstract][Full Text] [Related]
10. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia.
Autry RJ; Paugh SW; Carter R; Shi L; Liu J; Ferguson DC; Lau CE; Bonten EJ; Yang W; McCorkle JR; Beard JA; Panetta JC; Diedrich JD; Crews KR; Pei D; Coke CJ; Natarajan S; Khatamian A; Karol SE; Lopez-Lopez E; Diouf B; Smith C; Gocho Y; Hagiwara K; Roberts KG; Pounds S; Kornblau SM; Stock W; Paietta EM; Litzow MR; Inaba H; Mullighan CG; Jeha S; Pui CH; Cheng C; Savic D; Yu J; Gawad C; Relling MV; Yang JJ; Evans WE
Nat Cancer; 2020 Mar; 1(3):329-344. PubMed ID: 32885175
[TBL] [Abstract][Full Text] [Related]
11. Repurposing anthelmintic agents to eradicate resistant leukemia.
Mezzatesta C; Abduli L; Guinot A; Eckert C; Schewe D; Zaliova M; Vinti L; Marovca B; Tsai YC; Jenni S; Aguade-Gorgorio J; von Stackelberg A; Schrappe M; Locatelli F; Stanulla M; Cario G; Bourquin JP; Bornhauser BC
Blood Cancer J; 2020 Jun; 10(6):72. PubMed ID: 32591499
[TBL] [Abstract][Full Text] [Related]
12. Mutual antagonism between glucocorticoid and canonical Wnt signaling pathways in B-cell acute lymphoblastic leukemia.
Bergeron BP; Barnett KR; Bhattarai KR; Mobley RJ; Hansen BS; Brown A; Kodali K; High AA; Jeha S; Pui CH; Peng J; Pruett-Miller SM; Savic D
bioRxiv; 2023 May; ():. PubMed ID: 36711662
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Novel and Potent LCK Inhibitor for Leukemia Treatment via Deep Learning and Molecular Docking.
Guo H; Shen ZY; Yuan YY; Chen RF; Yang JY; Liu XC; Zhang Q; Pan QY; Ding JJ; He XJ; Zhang QN; Dong XW; Zhou KS
J Chem Inf Model; 2024 Jun; ():. PubMed ID: 38847742
[TBL] [Abstract][Full Text] [Related]
14. The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia.
Shah K; Ahmed M; Kazi JU
NPJ Precis Oncol; 2021 Feb; 5(1):13. PubMed ID: 33597638
[TBL] [Abstract][Full Text] [Related]
15. Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.
Bornschein S; Demeyer S; Stirparo R; Gielen O; Vicente C; Geerdens E; Ghesquière B; Aerts S; Cools J; de Bock CE
Leukemia; 2018 Apr; 32(4):941-951. PubMed ID: 29151585
[TBL] [Abstract][Full Text] [Related]
16. Leukemia-specific delivery of mutant NOTCH1 targeted therapy.
Roti G; Qi J; Kitara S; Sanchez-Martin M; Saur Conway A; Varca AC; Su A; Wu L; Kung AL; Ferrando AA; Bradner JE; Stegmaier K
J Exp Med; 2018 Jan; 215(1):197-216. PubMed ID: 29158376
[TBL] [Abstract][Full Text] [Related]
17. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
18. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.
O'Connor D; Enshaei A; Bartram J; Hancock J; Harrison CJ; Hough R; Samarasinghe S; Schwab C; Vora A; Wade R; Moppett J; Moorman AV; Goulden N
J Clin Oncol; 2018 Jan; 36(1):34-43. PubMed ID: 29131699
[TBL] [Abstract][Full Text] [Related]
19. Whole-genome DNA methylation characteristics in pediatric precursor B cell acute lymphoblastic leukemia (BCP ALL).
Chaber R; Gurgul A; Wróbel G; Haus O; Tomoń A; Kowalczyk J; Szmatoła T; Jasielczuk I; Rybka B; Ryczan-Krawczyk R; Duszeńko E; Stąpor S; Ciebiera K; Paszek S; Potocka N; Arthur CJ; Zawlik I
PLoS One; 2017; 12(11):e0187422. PubMed ID: 29125853
[TBL] [Abstract][Full Text] [Related]
20. The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment.
El Zawily A; McEwen E; Toosi B; Vizeacoumar FS; Freywald T; Vizeacoumar FJ; Freywald A
Sci Rep; 2017 Nov; 7(1):14767. PubMed ID: 29116180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
